S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
REYKJAVIK - Biotech company Alvotech (NASDAQ: ALVO), currently valued at $3.15 billion, has completed a private placement of 7.5 million treasury shares to approximately 40 institutional investors, according to a company statement released Wednesday. According to InvestingPro data, the company has demonstrated remarkable growth with a 414% revenue increase in the last twelve months.
The placement, which was conducted on June 4, attracted investors primarily from Sweden, Norway, and the UK, who accounted for about 60% of demand, while US-based funds represented approximately 30%. Over 80% of the allocated shares and Swedish Depositary Receipts (SDRs) went to investors who were not previously Alvotech shareholders. The company maintains a healthy gross profit margin of 61% and shows promising financial metrics, as detailed in the comprehensive research available on InvestingPro.
The transaction involved the transfer of treasury shares previously held by Alvotech’s subsidiary, Alvotech Manco ehf. The company noted that approximately 8.5 million SDRs are already trading on Nasdaq Stockholm.
"This placement will further diversify and strengthen Alvotech’s shareholder base and increase free float of SDRs on Nasdaq Stockholm," said Róbert Wessman, chairman and CEO of Alvotech, in the press release.
Alvotech specializes in the development and manufacture of biosimilar medicines. The company currently has two approved biosimilars on the market - alternatives to Humira (adalimumab) and Stelara (ustekinumab) - and nine additional biosimilar candidates in its development pipeline.
The company has established commercial partnerships with various pharmaceutical companies worldwide, including Teva Pharmaceuticals in the US, STADA Arzneimittel AG in the EU, and Fuji Pharma in Japan, among others across Asia, South America, Africa, and the Middle East.
The financial terms of the private placement were not disclosed in the announcement.
In other recent news, Alvotech reported impressive first-quarter earnings and revenue results that exceeded analyst expectations. The company achieved adjusted earnings per share of $0.35, significantly surpassing the consensus estimate of $0.03. Revenue for the quarter surged by 786% year-over-year to $109.9 million, driven by strong product launches and manufacturing efficiencies. Alvotech’s product revenue increased substantially, with successful sales of its biosimilars AVT02 and AVT04, as well as the U.S. launch of SELARSDI. The company also raised its full-year 2025 guidance, projecting revenue between $600-$700 million and adjusted EBITDA of $200-$280 million.
In another development, Dr. Reddy’s Laboratories announced a collaboration and license agreement with Alvotech to co-develop a biosimilar candidate to Keytruda®, a prominent cancer treatment. This partnership aims to leverage both companies’ strengths in the biosimilar market, with shared responsibilities and costs in development and manufacturing. The collaboration is expected to enhance Dr. Reddy’s presence in the oncology sector, aligning with its strategic goals. Meanwhile, UBS analysts highlighted challenges in the US generic drug market, noting limited cost pass-through capabilities for companies due to market diversity and competition. They also pointed out that recent executive orders promoting biosimilars lack the specifics needed to significantly impact the sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.